# Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer

> **NCT01893294** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 1 (actual)

## Conditions studied

- Duct Cell Adenocarcinoma of the Pancreas
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** gemcitabine hydrochloride
- **DRUG:** fluorouracil
- **RADIATION:** radiation therapy
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01893294
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-10-30
- **Final completion:** 2015-10-30
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893294, "Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01893294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*